Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSS06 · 1 trial · 2 indications
All adverse events occurring during the entire study period will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 5.0).
| Arm | Type | Description |
|---|---|---|
| Low-dose group | EXPERIMENTAL | SSS06, 200 μg, administered every 3 weeks, given 4 times |
| medium-dose group | EXPERIMENTAL | SSS06, 500 μg, administered every 3 weeks, given 4 times |
| high-dose group | EXPERIMENTAL | SSS06, 800 μg, administered every 3 weeks, given 4 times |
| Positive control group | PLACEBO_COMPARATOR | EPO, 36000 IU, administered every weeks, given 12 times |
| Name | Type | Description |
|---|---|---|
| SSS06 | DRUG | SSS06 is a highly glycosylated, long-acting recombinant protein product produced through recombinant gene technology by introducing site-specific mutations into the rHuEPO gene. |
| rhEPO | DRUG | a recombinant human erythropoietin injection. |
Inclusion Criteria: * Male or female participants aged ≥18 years at the time of signing the informed consent. * Histologically or cytologically confirmed diagnosis of non-myeloid malignancies. * Chemotherapy-induced anemia defined as hemoglobin (Hb) ≤100 g/L at screening, with a documented decrease...
SSS06 is an investigational small molecule being developed for chemotherapy-induced anemia in patients with non-myeloid malignancies. It is currently in Phase 2 clinical development and has not been approved by the FDA.
SSS06 is a small molecule designed to treat chemotherapy-induced anemia. Its specific molecular target has not been disclosed in available clinical trial information.
SSS06 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SBFM.
SSS06 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval.
SSS06 is being studied in a Phase 2 trial (NCT06854276) for chemotherapy-induced anemia in non-myeloid malignancies. This randomized, double-blind, placebo-controlled trial plans to enroll 80 participants aged 18 years and older.
No, SSS06 is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for chemotherapy-induced anemia.